[{"id":"84b9efcf-36bd-4449-8f61-5a867dd8b5f1","acronym":"NCI-2020-04163","url":"https://clinicaltrials.gov/study/NCT04435691","created_at":"2021-01-18T21:21:23.231Z","updated_at":"2025-02-25T16:37:56.003Z","phase":"Phase 1/2","brief_title":"Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia","source_id_and_acronym":"NCT04435691 - NCI-2020-04163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-06"},{"id":"963274c2-ef1a-43d9-bccd-99053c776187","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599634","created_at":"2023-06-02T17:05:43.963Z","updated_at":"2025-02-25T16:53:20.802Z","phase":"Phase 1","brief_title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","source_id_and_acronym":"NCT04599634","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 06/20/2024","study_completion_date":" 06/20/2024","last_update_posted":"2025-02-04"},{"id":"db660b09-0f52-4a82-9f38-79007e8d5211","acronym":"MORPHEUS mUC","url":"https://clinicaltrials.gov/study/NCT03869190","created_at":"2021-01-18T19:04:50.965Z","updated_at":"2025-02-25T13:18:52.965Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","source_id_and_acronym":"NCT03869190 - MORPHEUS mUC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 05/21/2026","study_completion_date":" 05/21/2026","last_update_posted":"2025-01-03"},{"id":"1a85dab3-0f07-4f86-8f14-7eca6a3d7503","acronym":"ELEVATE HNSCC","url":"https://clinicaltrials.gov/study/NCT04854499","created_at":"2021-04-22T20:53:31.234Z","updated_at":"2024-07-02T16:35:02.553Z","phase":"Phase 2","brief_title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04854499 - ELEVATE HNSCC","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • 5-fluorouracil • Yutuo (zimberelimab) • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-05-20"},{"id":"da2b0979-fceb-4b41-a878-bc533fb0df47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807126","created_at":"2023-04-11T14:03:25.975Z","updated_at":"2024-07-02T16:35:06.439Z","phase":"Phase 1","brief_title":"Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations","source_id_and_acronym":"NCT05807126","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3","pipe":" | ","alterations":" HR positive • BRCA mutation • CD47 expression","tags":["IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRCA mutation • CD47 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • magrolimab (ONO-7913)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/06/2026","primary_completion_date":" 12/06/2026","study_txt":" Completion: 12/06/2026","study_completion_date":" 12/06/2026","last_update_posted":"2024-05-02"},{"id":"df1fa759-f871-48f7-b168-7af2f5b18c2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046482","created_at":"2023-09-21T15:11:06.409Z","updated_at":"2024-07-02T16:35:09.810Z","phase":"Phase 2","brief_title":"Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06046482","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • SIRPA","pipe":"","alterations":" ","tags":["PD-L1 • SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • docetaxel • magrolimab (ONO-7913)"],"overall_status":"Suspended","enrollment":" Enrollment 57","initiation":"Initiation: 11/28/2023","start_date":" 11/28/2023","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2024-04-12"},{"id":"07e46b79-8fde-4376-b4a4-3d01c1ae210f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03558139","created_at":"2021-01-18T17:30:51.613Z","updated_at":"2025-02-25T16:07:59.888Z","phase":"Phase 1","brief_title":"Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy","source_id_and_acronym":"NCT03558139","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • magrolimab (ONO-7913)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 12/03/2020","primary_completion_date":" 12/03/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2024-04-01"},{"id":"12fc2fab-0693-4b13-abf9-14c2d2d11df7","acronym":"ELEVATELung\u0026UC","url":"https://clinicaltrials.gov/study/NCT04827576","created_at":"2021-04-01T15:52:23.578Z","updated_at":"2024-07-02T16:35:13.353Z","phase":"Phase 2","brief_title":"Study of Magrolimab in Patients With Solid Tumors","source_id_and_acronym":"NCT04827576 - ELEVATELung\u0026UC","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • ALK • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-21"},{"id":"71d0abaf-a3de-40e4-9de3-0a76efd7b3a2","acronym":"ELEVATE TNBC","url":"https://clinicaltrials.gov/study/NCT04958785","created_at":"2022-04-08T23:52:35.380Z","updated_at":"2024-07-02T16:35:14.392Z","phase":"Phase 2","brief_title":"Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04958785 - ELEVATE TNBC","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-15"},{"id":"ef136651-523a-43f8-b7a8-66380c3550f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02953782","created_at":"2021-01-18T14:30:28.655Z","updated_at":"2024-07-02T16:36:33.960Z","phase":"Phase 1b/2","brief_title":"Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer","source_id_and_acronym":"NCT02953782","lead_sponsor":"Gilead Sciences","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • oxaliplatin • irinotecan • magrolimab (ONO-7913)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 11/02/2016","start_date":" 11/02/2016","primary_txt":" Primary completion: 02/10/2020","primary_completion_date":" 02/10/2020","study_txt":" Completion: 02/10/2020","study_completion_date":" 02/10/2020","last_update_posted":"2021-03-01"}]